Patent SG-11201811237W-A (SG)
Title: Combination therapies
Inventor: KUTOK JEFFERY
IPC: A61K31/52
Filed: 2017-06-23
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIP0 I PCT Iiiimmomiolollmolommoolomoilloomommom (10) International Publication Number WO 2017/223422 Al (51) International Patent Classification: A61K 31/52 (2006.01) A61K 39/395 (2006.01) A61K 31/497 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/038966 (22) International Filing Date: 23 June 2017 (23.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/354,637 24 June 2016 (24.06.2016) US (71) Applicant: INFINITY PHARMACEUTICALS, INC. [US/US]; 780 Memorial Drive, Cambridge, MA 02139 (US). (72) Inventor: KUTOK, Jeffery, L.; 9 Oak Hill Road, Natick, MA 01760 (US). (74) Agent: BRUNER, Michael, J. et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: COMBINATION THERAPIES Isobologram 1 None 1 1500 1 H9 I None 1 384 1 15u1 I GM I Z Factor I ATP Lite 172h I I I I I I I I I I I I I I I I I I I I I I 0 .5 1 Selinexor / .93uM FIG.1 (57) : Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceu- tically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a checkpoint modulator, 2) an XPO1 inhibitor, 3) an anti-CD19 antibody, 4) a TLR agonist, 5) a STING agonist, or 6) a F1t3 ligand, or a combination thereof. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer. [Continued on next page] WO 2017/223422 Al MIDEDIM0110101011101011100101101111001E0HOII11EHOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))